FR2856685A1 - Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent

Info

Publication number
FR2856685A1
FR2856685A1 FR0307670A FR0307670A FR2856685A1 FR 2856685 A1 FR2856685 A1 FR 2856685A1 FR 0307670 A FR0307670 A FR 0307670A FR 0307670 A FR0307670 A FR 0307670A FR 2856685 A1 FR2856685 A1 FR 2856685A1
Authority
FR
France
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
thiazolylpiperidine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0307670A
Other languages
English (en)
Other versions
FR2856685B1 (fr
Inventor
Philippe Guedat
Francois Collonges
Herve Dumas
Jean Yves Ortholand
Jacques Decerprit
Jacques Barbanton
Richard J Foster
Peter Kane
Bernd Wendt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0307670A priority Critical patent/FR2856685B1/fr
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to CNA2004800157394A priority patent/CN1809560A/zh
Priority to ES04735742T priority patent/ES2323463T3/es
Priority to EP04735742A priority patent/EP1636218B1/fr
Priority to JP2006515818A priority patent/JP4629666B2/ja
Priority to CA2531011A priority patent/CA2531011C/fr
Priority to KR1020057024663A priority patent/KR20060024812A/ko
Priority to DE602004020223T priority patent/DE602004020223D1/de
Priority to US10/561,989 priority patent/US7674803B2/en
Priority to MXPA05013521A priority patent/MXPA05013521A/es
Priority to AU2004253649A priority patent/AU2004253649B2/en
Priority to RU2006101890/04A priority patent/RU2006101890A/ru
Priority to AT04735742T priority patent/ATE426599T1/de
Priority to PCT/EP2004/005931 priority patent/WO2005003128A1/fr
Priority to BRPI0411721-2A priority patent/BRPI0411721A/pt
Priority to TW093117985A priority patent/TW200518751A/zh
Priority to ARP040102230A priority patent/AR044909A1/es
Publication of FR2856685A1 publication Critical patent/FR2856685A1/fr
Application granted granted Critical
Publication of FR2856685B1 publication Critical patent/FR2856685B1/fr
Priority to ZA200600690A priority patent/ZA200600690B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Dérivés de thiazolylpipéridine, leurs procédés de préparation, les compositions pharmaceutiques qui les contiennent et leurs applications dans le traitement des hypertriglycéridémies, des hypercholestérolémies et des dyslipidémies.La présente invention concerne des dérivés de thiazolylpipéridine de formule générale (I) :dans laquelle :• A représente un radical choisi parmi les radicaux a1 et a2 suivants :• G représente une liaison ou un radical divalent choisi parmi les groupements g1, g2 et g3 suivants :• et R1, R2, R2', R3, R4, R5, Y et Z sont tels que définis dans la description.Application des composés de formule (I) au traitement des hypertriglycéridémies, des hypercholestérolémies et des dyslipidémies.
FR0307670A 2003-06-25 2003-06-25 Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent Expired - Fee Related FR2856685B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR0307670A FR2856685B1 (fr) 2003-06-25 2003-06-25 Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
RU2006101890/04A RU2006101890A (ru) 2003-06-25 2004-06-02 Производные тиазолилпиперидина в качестве ингибиторов мпб
EP04735742A EP1636218B1 (fr) 2003-06-25 2004-06-02 Derives de la thiazolylpiperidine, inhibiteurs de la mtp
JP2006515818A JP4629666B2 (ja) 2003-06-25 2004-06-02 ｍｔｐ阻害剤としてのチアゾリルピペリジン誘導体
CA2531011A CA2531011C (fr) 2003-06-25 2004-06-02 Derives de la thiazolylpiperidine, inhibiteurs de la mtp
KR1020057024663A KR20060024812A (ko) 2003-06-25 2004-06-02 Ｍｔｐ 저해제로서의 티아졸일피페리딘 유도체
DE602004020223T DE602004020223D1 (de) 2003-06-25 2004-06-02 Thiazolylpiperidin derivate als mtp inhibitoren
US10/561,989 US7674803B2 (en) 2003-06-25 2004-06-02 Thiazolypiperidine derivatives as MTP inhibitors
MXPA05013521A MXPA05013521A (es) 2003-06-25 2004-06-02 Derivados de tiazolilpiperidina como inhibidores de mtp.
PCT/EP2004/005931 WO2005003128A1 (fr) 2003-06-25 2004-06-02 Derives de la thiazolylpiperidine, inhibiteurs de la mtp
CNA2004800157394A CN1809560A (zh) 2003-06-25 2004-06-02 作为mtp抑制剂的噻唑基哌啶衍生物
ES04735742T ES2323463T3 (es) 2003-06-25 2004-06-02 Derivados de tiazolilpiperidina como inhibidores de la mtp.
AU2004253649A AU2004253649B2 (en) 2003-06-25 2004-06-02 Thiazolylpiperidine derivatives as MTP inhibitors
BRPI0411721-2A BRPI0411721A (pt) 2003-06-25 2004-06-02 derivados de tiazolilpiperidina como inibidores de mtp
AT04735742T ATE426599T1 (de) 2003-06-25 2004-06-02 Thiazolylpiperidin derivate als mtp inhibitoren
TW093117985A TW200518751A (en) 2003-06-25 2004-06-21 Thiazolylpiperidine derivatives, processes for the preparation thereof, pharmaceutical compositions comprising same, and applications thereof in the tre atment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia
ARP040102230A AR044909A1 (es) 2003-06-25 2004-06-25 Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
ZA200600690A ZA200600690B (en) 2003-06-25 2006-01-24 Thiazolylpiperidine derivatives as MTP inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0307670A FR2856685B1 (fr) 2003-06-25 2003-06-25 Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
FR2856685A1 true FR2856685A1 (fr) 2004-12-31
FR2856685B1 FR2856685B1 (fr) 2005-09-23

Family

ID=33515396

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0307670A Expired - Fee Related FR2856685B1 (fr) 2003-06-25 2003-06-25 Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent

Country Status (18)

Country Link
US (1) US7674803B2 (fr)
EP (1) EP1636218B1 (fr)
JP (1) JP4629666B2 (fr)
KR (1) KR20060024812A (fr)
CN (1) CN1809560A (fr)
AR (1) AR044909A1 (fr)
AT (1) ATE426599T1 (fr)
AU (1) AU2004253649B2 (fr)
BR (1) BRPI0411721A (fr)
CA (1) CA2531011C (fr)
DE (1) DE602004020223D1 (fr)
ES (1) ES2323463T3 (fr)
FR (1) FR2856685B1 (fr)
MX (1) MXPA05013521A (fr)
RU (1) RU2006101890A (fr)
TW (1) TW200518751A (fr)
WO (1) WO2005003128A1 (fr)
ZA (1) ZA200600690B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115805A3 (fr) * 2006-04-05 2008-06-05 European Molecular Biology Lab Embl Inhibiteurs de la kinase aurora
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
EP2009005A4 (fr) * 2006-04-19 2010-06-02 Astellas Pharma Inc Dérivé d'azolecarboxamide
WO2011051244A1 (fr) 2009-10-30 2011-05-05 Bayer Cropscience Ag Dérivés d'hétéroarylpipéridine et d'hétéroarylpipérazine
US8304547B2 (en) 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
CN116113406A (zh) * 2020-07-10 2023-05-12 密歇根大学董事会 Gas41抑制剂及其使用方法

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
BRPI0516958A (pt) * 2004-09-20 2008-03-25 4Sc Ag inibidores da nf-capab heterocìclicos
EP1637529A1 (fr) 2004-09-20 2006-03-22 4Sc Ag Nouveaux analogues de piperidin-4-yl-thiazole-carboxamide en tant qu'inhibiteurs de proliferation de lymphocytes T er leurs utilisations
US20100267717A1 (en) * 2005-07-29 2010-10-21 4Sc Ag Novel Heterocyclic NF-kB Inhibitors
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
TW200738701A (en) * 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
WO2007016979A2 (fr) * 2005-07-29 2007-02-15 4Sc Ag Nouveaux inhibiteurs heterocycliques de nf-kb
EP1945635B1 (fr) * 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Derives de thiazolyle piperidine utile comme modulateurs du recepteur h3
EP1832586A1 (fr) * 2006-03-10 2007-09-12 Oridis Biomed Forschungs- und Entwicklungs GmbH Derivés de thiazole-piperidine pour le traitement des des maladies hepatiques et pancréatiques
EP1834954A1 (fr) * 2006-03-15 2007-09-19 4Sc Ag Thiazoles comme inhibiteurs de NF-kB (inhibiteurs de proteasome)
EA200801838A1 (ru) * 2006-03-15 2009-02-27 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-kB
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008013622A2 (fr) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Amides azocycliques fongicides
MX2009004786A (es) * 2006-10-31 2009-06-05 Schering Corp Derivados de anilinopiperazina y sus metodos de uso.
AR063531A1 (es) * 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
JP5498168B2 (ja) * 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
BRPI0806214A2 (pt) 2007-01-25 2011-08-30 Du Pont composto, método para o controla das doenças vegetais causadas por patogenos vegetais fúngicos oomycete e composições fungicidas
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
CN101910165A (zh) * 2007-10-29 2010-12-08 先灵公司 作为蛋白质激酶抑制剂的噻唑衍生物
JP5529044B2 (ja) 2008-01-25 2014-06-25 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性複素環化合物
PT2280965E (pt) 2008-04-30 2012-11-13 Bayer Cropscience Ag Ésteres e tioésteres de ácido tiazol-4-carboxílico como agentes para a protecção de plantas
KR20110067052A (ko) * 2008-10-01 2011-06-20 바이엘 크롭사이언스 아게 식물 보호제로서의 헤테로사이클릴 치환된 티아졸
PL2358709T3 (pl) 2008-12-02 2014-06-30 Du Pont Grzybobójcze związki heterocykliczne
EP2404902A1 (fr) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Dérivés de la pipéridine et de la pyrrolidine dotés d'un antagonisme pour les récepteurs npy y5
EP2272846A1 (fr) * 2009-06-23 2011-01-12 Bayer CropScience AG Dérivés de thiazolylpipéridine en tant que fongicide
GEP20146079B (en) * 2009-08-12 2014-04-25 Syngenta Participations Ag Microbiocidal heterocycles
WO2011051243A1 (fr) 2009-10-29 2011-05-05 Bayer Cropscience Ag Combinaisons de composé actif
US8629286B2 (en) * 2009-12-22 2014-01-14 Syngenta Crop Protection, Llc Pyrazole derivatives
MX2012012460A (es) * 2010-04-28 2012-11-21 Bayer Cropscience Ag Derivados de cetoheteroarilpiperidina y de cetoheteroarilpiperazin a como fungicidas.
CA2812526A1 (fr) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Amides de chromene heterocyclique-piperidine spirocyclique utiles comme modulateurs des canaux ioniques
US8815775B2 (en) * 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
KR101848116B1 (ko) 2011-02-01 2018-04-11 바이엘 인텔렉쳐 프로퍼티 게엠베하 살진균제로서의 헤테로아릴 피페리딘 및 헤테로아릴 피페라진 유도체
BR112013019211A2 (pt) 2011-02-02 2021-07-06 Vertex Pharma amidas de piperidina espirocíclicas de pirrolopirazina como moduladores de canais de íon
CN103347879A (zh) * 2011-02-10 2013-10-09 先正达参股股份有限公司 杀微生物的吡唑衍生物
CN103443105A (zh) * 2011-02-18 2013-12-11 沃泰克斯药物股份有限公司 作为离子通道调节剂的苯并二氢吡喃-螺环哌啶酰胺
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2012131399A1 (fr) 2011-04-01 2012-10-04 Astrazeneca Ab Traitement thérapeutique
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2015018027A1 (fr) * 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Antagonistes thiazoles des récepteurs de l'orexine
WO2016086357A1 (fr) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Méthyl oxazoles antagonistes du récepteur d'orexine
EP3573619A4 (fr) * 2017-01-27 2020-10-28 SignalRX Pharmaceuticals, Inc. Thiénopyranones et furanopyranones en tant qu'inhibiteurs de kinase, de bromodomaine et de points de contrôle
KR20200018407A (ko) * 2017-04-28 2020-02-19 텍사스 칠드런스 하스피탈 표적화 나노입자
CN111196805A (zh) * 2018-11-17 2020-05-26 曲阜德禄生物科技有限公司 哌啶基噻唑甲酰胺类化合物合成方法与用途
AU2021270664B2 (en) * 2020-05-12 2024-05-30 Beijing Greatway Pharmaceutical Technology Co., Ltd. Compound for adjusting activity of NMDA receptor, and pharmaceutical composition and use thereof
CN120917015A (zh) * 2023-01-20 2025-11-07 元启(苏州)生物制药有限公司 Srpk1抑制剂和使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
WO2003047575A1 (fr) * 2001-12-04 2003-06-12 Glaxo Group Limited Derives de benzamide therapeutiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
CN1210267C (zh) * 2000-04-04 2005-07-13 史密斯克莱·比奇曼公司 用于抗菌的2－羟基－姆替林氨基甲酸酯衍生物
GB0230162D0 (en) * 2002-12-24 2003-02-05 Metris Therapeutics Ltd Compounds useful in inhibiting angiogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
WO2003047575A1 (fr) * 2001-12-04 2003-06-12 Glaxo Group Limited Derives de benzamide therapeutiques

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115805A3 (fr) * 2006-04-05 2008-06-05 European Molecular Biology Lab Embl Inhibiteurs de la kinase aurora
EP2009005A4 (fr) * 2006-04-19 2010-06-02 Astellas Pharma Inc Dérivé d'azolecarboxamide
US8163746B2 (en) 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
DE102007047735A1 (de) 2007-10-05 2009-04-09 Merck Patent Gmbh Thiazolderivate
US8304547B2 (en) 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
WO2011051244A1 (fr) 2009-10-30 2011-05-05 Bayer Cropscience Ag Dérivés d'hétéroarylpipéridine et d'hétéroarylpipérazine
CN116113406A (zh) * 2020-07-10 2023-05-12 密歇根大学董事会 Gas41抑制剂及其使用方法
EP4178571A4 (fr) * 2020-07-10 2024-07-17 The Regents Of The University Of Michigan Inhibiteurs de gas41 et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
JP4629666B2 (ja) 2011-02-09
CA2531011A1 (fr) 2005-01-13
ATE426599T1 (de) 2009-04-15
CN1809560A (zh) 2006-07-26
RU2006101890A (ru) 2007-07-27
FR2856685B1 (fr) 2005-09-23
ZA200600690B (en) 2007-05-30
AU2004253649B2 (en) 2009-09-24
EP1636218B1 (fr) 2009-03-25
US7674803B2 (en) 2010-03-09
EP1636218A1 (fr) 2006-03-22
ES2323463T3 (es) 2009-07-16
TW200518751A (en) 2005-06-16
DE602004020223D1 (de) 2009-05-07
BRPI0411721A (pt) 2006-05-23
JP2007506651A (ja) 2007-03-22
AR044909A1 (es) 2005-10-05
CA2531011C (fr) 2012-10-09
WO2005003128A1 (fr) 2005-01-13
KR20060024812A (ko) 2006-03-17
MXPA05013521A (es) 2006-03-09
AU2004253649A1 (en) 2005-01-13
US20070054939A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
MA29533B1 (fr) Derives de 2- amido-6-amino-8-oxopurine servant de modulateurs des recepteurs du type toll le traitement du cancer et d'infections virales, telles que l'hepatite c
TW200518751A (en) Thiazolylpiperidine derivatives, processes for the preparation thereof, pharmaceutical compositions comprising same, and applications thereof in the tre atment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia
MA30289B1 (fr) Dérivés d'amines
MA28130A1 (fr) Derives aryle et heteroaryle condenses utilises comme modulateurs du metabolisme et prophylaxie et traitement des troubles metaboliques.
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
WO2003104217A3 (fr) Promedicaments d'acides amines excitateurs
MA28747B1 (fr) Dérivés de pyridine
MA27427A1 (fr) Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie
MA27909A1 (fr) Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA27725A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA27121A1 (fr) Derives 2-(purin-9-yl)-tetrahydrofuran-3,4-diol
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
TNSN04151A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080229